Zhejiang Jolly PharmaceuticalLTD Dirección

Dirección controles de criterios 4/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Tao Wang

Chief Executive Officer (CEO)

CN¥1.0m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	6.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	4.8yrs
Promedio de permanencia en la Junta Directiva	5.4yrs

Actualizaciones recientes de la dirección

Recent updates

Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

May 13

A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

May 08

There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings

Mar 01

CEO

Tao Wang (55 yo)

6.3yrs

Permanencia

CN¥1,049,800

Compensación

Mr. Tao Wang serves as General Manager at Zhejiang Jolly Pharmaceutical Co., Ltd. since January 16, 2018 and also served as its Senior Manager and Deputy General Manager.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Tao Wang	General Manager	6.3yrs	CN¥1.05m	sin datos
Yuehong Shen	Deputy GM & Non-Independent Director	3.3yrs	CN¥737.50k	sin datos
Guofu Feng	Executive Deputy GM	2.1yrs	CN¥797.70k	0.093% CN¥ 11.0m
Jian Chen	Deputy General Manager	16.3yrs	CN¥606.40k	0.15% CN¥ 17.4m
Xiao Guo Peng	Deputy General Manager	6.3yrs	CN¥696.00k	sin datos
Xin Tan	Deputy General Manager	1.3yrs	CN¥717.30k	0.0027% CN¥ 319.5k

4.8yrs

Permanencia media

50.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 300181 se considera experimentado (4.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yuehong Shen	Deputy GM & Non-Independent Director	3.3yrs	CN¥737.50k	sin datos
Guofu Feng	Executive Deputy GM	7.3yrs	CN¥797.70k	0.093% CN¥ 11.0m
Youqiang Yu	Chairman	20.8yrs	CN¥1.05m	18.52% CN¥ 2.2b
Huifen Zhang	Non-Independent Director	3.3yrs	CN¥20.00k	sin datos
Liming Yao	Employee Supervisor	5.4yrs	sin datos	sin datos
Xuegen Zheng	Non-Independent Director	16.3yrs	CN¥20.00k	0.10% CN¥ 12.3m
Jian Jun Wang	Non-Independent Director	7.3yrs	CN¥20.00k	sin datos
Bin Pan	Independent Director	4.2yrs	CN¥60.00k	sin datos
Ping Wang	Independent Director	3.3yrs	CN¥60.00k	sin datos
Jian Zhu	Independent Director	3.3yrs	CN¥60.00k	sin datos
Chenghua Zhou	Chairman of the Supervisory Board	6.3yrs	sin datos	sin datos

5.4yrs

Permanencia media

51yo

Promedio de edad

Junta con experiencia: La junta directiva de 300181 se considera experimentada (5.3 años de antigüedad promedio).

Zhejiang Jolly PharmaceuticalLTD Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Zhejiang Jolly Pharmaceutical Co.,LTD, Annual General Meeting, May 10, 2024

Insufficient new directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Zhejiang Jolly Pharmaceutical Co.,LTD Approves Management Appointments

Recent updates

Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.14 in 1Q 2023)

Zhejiang Jolly Pharmaceutical Co.,LTD, Annual General Meeting, May 10, 2024

Zhejiang Jolly Pharmaceutical Co.,LTD to Report Q1, 2024 Results on Apr 19, 2024

Investor sentiment improves as stock rises 18%

Now 22% overvalued after recent price rise

There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings

Investor sentiment deteriorates as stock falls 16%

Insufficient new directors

Zhejiang Jolly Pharmaceutical Co.,LTD to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.11 in 2Q 2022)

Zhejiang Jolly Pharmaceutical Co.,LTD to Report First Half, 2023 Results on Aug 09, 2023

Zhejiang Jolly Pharmaceutical Co.,LTD Announces Cash Dividend on A Shares for the Year 2022, Payable on 30 May 2023

Zhejiang Jolly Pharmaceutical Co.,LTD Approves Cash Dividend for 2022

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings released: EPS: CN¥2.25 (vs CN¥0.29 in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.074 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.07 in 2Q 2021)

Investor sentiment improved over the past week

Zhejiang Jolly Pharmaceutical Co.,LTD Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 31 May 2022

Zhejiang Jolly Pharmaceutical Co.,Ltd Approves Cash Dividend for 2021

High number of new and inexperienced directors

Zhejiang Jolly Pharmaceutical Co.,LTD Proposes Cash Dividend for 2021

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorated over the past week

Zhejiang Jolly Pharmaceutical Co.,LTD announced that it expects to receive CNY 910 million in funding

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.074 (vs CN¥0.052 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.033 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Zhejiang Jolly Pharmaceutical Co.,Ltd Announces Final Cash Dividend for 2020, Payable on 31 May 2021

Zhejiang Jolly Pharmaceutical Co.,Ltd Approves Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥0.15 (vs CN¥0.042 in FY 2019)

Investor sentiment improved over the past week

New 90-day high: CN¥6.86

Full year 2020 earnings released: EPS CN¥0.14 (vs CN¥0.042 in FY 2019)

Zhejiang Jolly Pharmaceutical Co.,LTD to Report Fiscal Year 2020 Results on Apr 13, 2021

Zhejiang Jolly Pharmaceutical Co.,LTD Approves Management Appointments

Investor sentiment improved over the past week

New 90-day low: CN¥5.87

New 90-day low: CN¥6.12

New 90-day low: CN¥6.59

Third quarter earnings released

New 90-day high - CN¥8.10

Zhejiang Jolly Pharmaceutical Co.,LTD to Report First Half, 2020 Results on Aug 27, 2020

New 90-day high - CN¥6.39

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad